About this episode
After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual sales last year for its maker, Johnson and Johnson. Further Listening: - A Lawyer Says He Doesn't Need Help for Psychosis. His Family Disagrees. - America's Maternal Mental Health Crisis Further Reading: - J&J’s Ketamine-Derived Drug Is Taking Off - Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. Learn more about your ad choices. Visit megaphone.fm/adchoices